Cargando…
Addition of Rapamycin to Anti-CD3 Antibody Improves Long-Term Glycaemia Control in Diabetic NOD Mice
AIMS/HYPOTHESIS: Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing op...
Autores principales: | Perl, Shira, Perlman, Jordan, Weitzel, R. P., Phang, Oswald, Hsieh, Matthew M., Tisdale, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691209/ https://www.ncbi.nlm.nih.gov/pubmed/23826229 http://dx.doi.org/10.1371/journal.pone.0067189 |
Ejemplares similares
-
Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice
por: Valle, Andrea, et al.
Publicado: (2009) -
Long-Term Remission of Diabetes in NOD Mice Is Induced by Nondepleting Anti-CD4 and Anti-CD8 Antibodies
por: Yi, Zuoan, et al.
Publicado: (2012) -
Long-Term Vector Integration Site Analysis Following Retroviral Mediated Gene Transfer to Hematopoietic Stem Cells for the Treatment of HIV Infection
por: Hayakawa, Jun, et al.
Publicado: (2009) -
Glycaemia and critical care outcomes
por: Cecconi, M, et al.
Publicado: (2014) -
p53 and rapamycin are additive
por: Christy, Barbara, et al.
Publicado: (2015)